Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Abstract

The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

1 - 14 . (canceled) 
     
     
         15 . A medicament comprising an effervescent composition in solid form comprising:
 an acid-base system comprising an organic acid and a salt of the carbonate and/or bicarbonate anion; said salt being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,   a mixture comprising microcrystalline cellulose and arabinogalactan,   at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising:  Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli , Herpes simplex and  Haemophilus ducreyi,      the effervescent composition being formulated for treatment of a vaginal infection.   
     
     
         16 . The medicament in accordance with  claim 15 , wherein said composition is in the form of a tablet, ovule, lozenge or granules. 
     
     
         17 . The medicament in accordance with  claim 15 , wherein the salt of carbonate and/or bicarbonate anion is present in an amount comprised from 3 to 13% by weight, relative to the total weight of the composition. 
     
     
         18 . The medicament in accordance with  claim 15 , wherein the acid-base system consists of sodium bicarbonate and citric acid, and wherein the sodium bicarbonate is present in an amount comprised from 3 to 13% by weight, relative to the total weight of the composition. 
     
     
         19 . The medicament in accordance with  claim 15 , wherein said at least one probiotic bacterial strain belongs to at least one species selected from the group consisting of:  Lactobacillus plantarum, Lactobacillus pentosus, Lactobacillus casei, Lactobacillus casei  ssp.  paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus delbrueckii  ssp.  bulgaricus, Lactobacillus delbrueckii  ssp.  delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis  ssp.  lactis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum  or  Bifidobacterium infantis ; said at least one bacterial strain is preferably selected from among:  Lactobacillus salivarius  CRL 1328,  Lactobacillus paracasei  CRL 1289,  Lactobacillus  gasseri CRL 1259,  Lactobacillus  crispatus CRL 1251,  Lactobacillus  crispatus CRL 1266,  Lactobacillus acidophilus  CRL 1294,  Lactobacillus paracasei  LPC 00,  Lactobacillus plantarum  LP 02 and  Lactobacillus fermentum  LF 10. 
     
     
         20 . A medicament comprising an effervescent tablet in solid form comprising:
 an acid-base system comprising sodium bicarbonate and citric acid; said bicarbonate being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,   a mixture comprising microcrystalline cellulose and arabinogalactan in a ratio by weight comprised from 1:1 to 3:1,   at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising:  Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli , Herpes simplex and  Haemophilus ducreyi,      the effervescent composition being formulated for treatment of a vaginal infection.